Financial Performance - The erythritol industry faced unprecedented challenges during the reporting period, leading to oversupply and price declines, which negatively impacted sales revenue and profits[4]. - The company reported a year-on-year decline in both sales revenue and profit due to the dual impact of price and volume[4]. - The company's revenue for 2023 was ¥499,500,775.41, a decrease of 25.99% compared to ¥674,905,595.63 in 2022[22]. - The net profit attributable to shareholders for 2023 was ¥55,981,918.44, down 65.80% from ¥163,686,641.34 in the previous year[22]. - The basic earnings per share for 2023 was ¥0.28, a decline of 65.85% from ¥0.82 in 2022[22]. - The total assets at the end of 2023 amounted to ¥4,807,533,905.12, a decrease of 1.28% from ¥4,869,919,341.29 at the end of 2022[22]. - The net assets attributable to shareholders at the end of 2023 were ¥4,535,129,974.85, down 1.85% from ¥4,620,776,046.41 in 2022[22]. - The cash flow from operating activities for 2023 was ¥57,310,770.18, a decrease of 31.99% compared to ¥84,264,654.04 in 2022[22]. - The weighted average return on equity for 2023 was 1.23%, down from 3.80% in 2022[22]. - The company reported a decrease in net profit after deducting non-recurring gains and losses, which was ¥54,790,117.06 in 2023, down 66.25% from ¥162,331,457.53 in 2022[22]. - The company has experienced a significant decline in both revenue and profit margins over the past year, indicating potential challenges in market performance[22]. Market Trends and Industry Insights - The functional sugar market, particularly erythritol, has seen a compound annual growth rate (CAGR) of 48.9% from 2015 to 2022, indicating rapid industry growth[34]. - China accounted for 78.9% of the global erythritol production in 2022, with a total output of approximately 139,000 tons[34]. - The functional sugar industry is supported by favorable government policies aimed at reducing sugar consumption, creating a conducive environment for growth[42]. - The functional sugar industry in China is experiencing rapid growth, driven by increasing consumer demand for health-oriented, low-sugar, and sugar-free products[44]. - The market size for the sugar-free beverage industry in China is projected to reach approximately 748.9 billion CNY by 2027, with a compound annual growth rate (CAGR) of 38.1% from 2015 to 2023[47]. - Erythritol remains the leading sugar substitute in the zero-sugar and low-sugar beverage market, with widespread acceptance among consumers and regulatory bodies[46]. Product Development and Innovation - The company is focusing on developing functional foods and expanding its product offerings in response to market demands[22]. - The company is actively expanding its market presence by participating in food exhibitions in countries such as the USA, Russia, Brazil, Japan, South Korea, Thailand, and Dubai[97]. - The company is increasing its R&D efforts, focusing on new product development in the functional sugar sector, with products like high-quality stevia, sodium hyaluronate, and tagatose in the pipeline[100]. - The company has developed over 20 varieties of blended sugars, including monk fruit and stevia blends, tailored to customer specifications[59]. - The company has developed key applications for erythritol, including table sugar, beverages, and confectionery, leveraging its natural, near-zero calorie, and pure taste characteristics[61]. - The company is currently developing a fermentation process for rare sugars, which is expected to create new business opportunities[117]. - The company has established a research subsidiary and various research platforms to enhance its innovation capabilities and maintain competitive advantages in product quality and cost[94]. Strategic Initiatives and Future Outlook - The company aims to maintain a market-leading position in erythritol while developing competitive functional sugars and other sugar products, targeting sectors such as special medical foods, cosmetics, and drug delivery systems[148]. - The company plans to adopt a product development strategy of "one generation listed, one generation in research, and one generation in reserve" to ensure a steady pipeline of new products[149]. - The company is committed to enhancing its research and development capabilities by collaborating with leading food fermentation research institutions to diversify its product offerings[150]. - The company plans to increase its workforce by 10% to support the anticipated growth in production and R&D activities[193]. - The management team has emphasized the importance of innovation, with a commitment to allocate 15% of revenue towards R&D initiatives[194]. Governance and Compliance - The company has established a board of directors consisting of 9 members, including 3 independent directors, complying with relevant laws and regulations[166]. - The company has a supervisory board with 3 members, including 1 employee supervisor, ensuring compliance and oversight of major company matters[167]. - The company maintains independence from its controlling shareholders, with no unauthorized use of company funds or interference in decision-making[168]. - The company has implemented a performance evaluation and incentive mechanism for directors and senior management, aligning with its development status[169]. - The company adheres to strict information disclosure practices, ensuring transparency and fairness for all investors[171]. - The internal audit system is effectively implemented, enhancing governance and ensuring the achievement of operational goals[172]. Customer and Market Risks - Erythritol accounted for 81.67% of the company's total revenue in 2023, indicating a risk due to the company's reliance on a single product line[153]. - The top five customers contributed 36.12% of total annual sales, indicating a high customer concentration risk[159]. - The company aims to diversify its customer base and develop new products to mitigate risks associated with major customer changes[159]. - The company recognizes the risk of intensified competition and market demand fluctuations, which could impact sales and pricing of erythritol products[153]. - Raw materials accounted for 63.83% of the main business costs in 2023, with fluctuations in corn prices posing a risk to profitability[155].

Financial Performance - The company's revenue for the reporting period reached ¥376,846,697.32, representing a 60.15% increase compared to ¥235,313,762.07 in the same period last year [22]. - Net profit attributable to shareholders was ¥51,913,757.70, up 55.82% from ¥33,317,037.94 year-on-year [22]. - The net cash flow from operating activities surged to ¥22,872,518.72, a significant increase of 9,206.18% compared to ¥245,777.66 in the previous year [22]. - Basic earnings per share increased to ¥0.26, reflecting a 62.50% rise from ¥0.16 in the same period last year [22]. - Total assets at the end of the reporting period were ¥4,847,401,468.95, a slight increase of 0.83% from ¥4,807,533,905.12 at the end of the previous year [22]. - The gross margin for erythritol was 9.09%, with revenue from this product at ¥311,460,240.16, reflecting a 51.85% increase year-over-year [119]. - The gross margin for blended sugars was 87.79%, showing a slight decrease of 0.40% year-on-year [87]. - The company reported a total revenue of ¥376,846,697.32, with a year-on-year growth of 60.15% [89]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 1.5 RMB per 10 shares to all shareholders, based on a total of 201,865,000 shares [4]. - The total distributable profit amounts to 738,596,018.68 CNY, indicating a strong financial position for future investments [160]. - The company plans to distribute a cash dividend of CNY 1.5 per 10 shares, totaling CNY 30,279,750, based on a total share capital of 201,865,000 shares after accounting for repurchased shares [162]. - The company is in a growth phase and has significant capital expenditure plans, ensuring that cash dividends will not fall below 20% of profit distribution in the future [160]. Market and Industry Insights - The functional sugar industry is experiencing rapid growth, driven by increasing health consciousness and demand for low-calorie sweeteners, with a focus on products like erythritol, allulose, and high-quality stevia [31]. - Global demand for erythritol is projected to reach 238,000 tons by 2024, with a compound annual growth rate (CAGR) of 22% from 2020 to 2024, indicating strong market demand [33]. - The erythritol market is facing supply-demand imbalances due to excessive production capacity, leading to intensified competition and price declines, with prices dropping from 40,000 RMB/ton in 2021 to 9,500 RMB/ton in the first half of 2023 [39]. - The European Union initiated an anti-dumping investigation on Chinese erythritol products, imposing temporary duties ranging from 31.9% to 235.6%, affecting competitiveness in the EU market [41]. - The global allulose market size was $210 million at the end of 2020 and is expected to grow to $450 million by 2030, with a CAGR of 9.1% [45]. - The company is focusing on expanding into emerging markets in Southeast Asia, India, the Middle East, and South America to mitigate risks from concentrated markets [150]. Production and Technology - The company has developed a yeast-based enzymatic production process, achieving small-scale production with a planned capacity of 3,000 tons per year by July 2024 [59][60]. - The new production technology significantly reduces costs and improves efficiency, providing a competitive advantage in the high-quality sweetener market [60]. - The company has implemented an ERP system integrated with production automation, enhancing operational efficiency and reducing production costs [104]. - The company has developed advanced fermentation technology, achieving a conversion rate of over 54.5% for erythritol production, significantly higher than previous rates [102]. Governance and Compliance - The company held its annual general meeting on May 15, 2024, with 49.11% of investors participating, approving key reports and future shareholder return plans [157]. - The company has undergone a board restructuring, with new appointments for key positions including Chairman and General Manager effective July 19, 2024 [158][159]. - The company emphasizes sustainable development, balancing economic and social benefits while adhering to legal operations and tax obligations [169]. - The company has established a complete supplier management system to ensure the protection of supplier rights and promote mutual development [171]. Environmental and Social Responsibility - The company has invested in green energy initiatives, including a stable distributed photovoltaic power generation project that meets part of its electricity needs [168]. - The company has maintained compliance with environmental regulations, with all monitoring indicators meeting national standards [167]. - The company actively pursues environmental protection responsibilities, integrating ecological requirements into its business operations for sustainable development [172]. - The company prioritizes employee rights, providing a safe working environment and adhering to labor laws, while also focusing on employee development and training [171]. Risks and Challenges - The company is facing a temporary anti-dumping tax of 156.7% on erythritol exports to the EU, impacting its market presence in that region [150]. - The production and sales of erythritol have decreased due to intensified competition and a slowdown in downstream customer demand, leading to lower prices [134]. - The company acknowledges the potential risks to future profits due to internal and external factors, and investors should not rely solely on the measures outlined for investment decisions [179].

Financial Performance - The company's operating revenue for Q3 2024 reached ¥138,076,442.87, representing a 19.16% increase year-over-year, and a total of ¥514,923,140.19 for the year-to-date, up 46.62% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2024 was ¥29,093,416.24, a significant increase of 248.18% year-over-year, with a year-to-date net profit of ¥81,007,173.94, up 94.39%[4] - Basic and diluted earnings per share for Q3 2024 were both ¥0.14, reflecting a 250.00% increase compared to the same period last year, with year-to-date earnings per share at ¥0.40, up 90.48%[4] - Total operating revenue for the current period reached ¥514,923,140.19, a significant increase of 46.5% compared to ¥351,192,635.35 in the previous period[27] - Operating profit for the current period was ¥85,493,929.39, up 90.5% from ¥44,871,999.14 in the previous period[28] - Net profit attributable to the parent company was ¥81,007,173.94, representing a 94.3% increase from ¥41,672,900.57 in the previous period[28] - Basic and diluted earnings per share increased to ¥0.40 from ¥0.21, reflecting a growth of 90.5%[28] - The company reported a tax expense of ¥4,736,208.37, compared to ¥3,377,080.39 in the previous period, indicating an increase of 39.9%[28] - The company recorded other income of ¥1,546,304.35, up from ¥821,692.01 in the previous period, marking an increase of 88.2%[27] Assets and Liabilities - The company's total assets at the end of Q3 2024 were ¥4,763,833,724.23, a slight decrease of 0.91% from the end of the previous year[4] - As of September 30, 2024, the total assets of the company amounted to ¥4,763,833,724.23, a slight decrease from ¥4,807,533,905.12 at the beginning of the period[25][26] - The company’s non-current assets totaled ¥1,407,629,556.93, compared to ¥4,485,720,051.15 at the beginning of the period, showing a significant decrease[26] - Total current liabilities were reported at ¥187,482,982.83, down from ¥224,197,013.02, indicating a reduction of about 16.4%[26] - The company’s retained earnings stood at ¥734,493,416.48, slightly down from ¥742,459,712.82, reflecting a decrease of about 1.1%[26] - The company’s total liabilities were reported at ¥239,671,475.10, down from ¥272,403,930.27, indicating a decrease of approximately 12%[26] Cash Flow - Cash flow from operating activities for the year-to-date was ¥6,970,913.77, down 68.23% year-over-year, primarily due to a reduction in bill settlements with suppliers[12] - Net cash flow from operating activities was ¥6,970,913.77, down 68.3% from ¥21,942,222.52 in the previous period[29] - Cash flow from investing activities generated a net inflow of ¥58,019,291.88, compared to a net outflow of ¥251,828,518.11 in the previous period[29] - Cash and cash equivalents at the end of the period totaled ¥80,824,019.10, down from ¥105,046,022.69 at the end of the previous period[30] - Cash and cash equivalents decreased to ¥86,800,655.34 from ¥108,808,330.03, reflecting a decline of approximately 20.2%[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 14,096, with the largest shareholder holding 46.23% of the shares[14] - The top 10 unrestricted shareholders hold a total of 56,000,000 shares, with the largest shareholder, Lü Xian, owning 12,852,000 shares, representing 6.35% of total shares[15] - Wang Shen, another significant shareholder, holds 5,265,910 shares, accounting for 2.60% of total shares[15] - The South China Xin Tai Private Fund Management Company, through its various funds, collectively holds 6,150,218 shares, which is approximately 3.04% of total shares[15] - The company has a total of 92,946,000 restricted shares held by Nie Zaijian, which will be released on August 10, 2025[19] - The total number of shares held by the top 10 unrestricted shareholders represents a significant portion of the company's equity, indicating strong institutional interest[15] - The company has seen a notable increase in the number of shares held by individual shareholders, with Li Dechun increasing his holdings to 2,880,000 shares[19] - The shareholder structure indicates a concentration of ownership, with the top three shareholders holding over 11% of the total shares[15] - The company has not reported any changes in the number of shares due to margin trading activities among the top shareholders[17] - The total number of shares held by Beijing Yi'an Capital Management Co., Ltd. is 1,731,779, representing 0.86% of total shares[17] - The company has a clear strategy for managing restricted shares, with specific release dates outlined for key executives[19] Governance and Strategy - The company completed the election of its fifth board of directors and supervisory board, ensuring continuity and stability in governance[21] - The company plans to expand its operational locations, with a new site at 101 Wutong 10th Road, Binbei District, Binzhou City[23] - The company has appointed Rongcheng Accounting Firm as its new external auditor for the 2024 fiscal year, following the termination of its previous auditor due to regulatory issues[24] - The board of directors held a meeting on October 30, 2024, to discuss future strategies[32] Accounting Standards and Reporting - The new accounting standards will be implemented starting from 2024, affecting the financial statements from the beginning of the year[31] - The company is preparing for the first-time execution of new accounting standards, which may impact financial reporting[31] - The third quarter report of Shandong Sanyuan Biotechnology Co., Ltd. has not been audited[32] - There are no specific performance summaries or user data provided in the documents[31][32] - No future outlook or performance guidance has been disclosed in the available content[31][32] - There is no mention of new product or technology development in the provided documents[31][32] - Market expansion or acquisition strategies are not detailed in the current reports[31][32] - The third quarter report does not include any financial metrics or performance indicators[31][32] - The documents do not provide any insights into new strategies being adopted by the company[31][32]

三元生物（301206）公告，2025年第一季度营收为1.5亿元，同比下降21.73%；净利润为2491.4万元， 同比增长2.75%。 ...

中信建投证券股份有限公司 关于对山东三元生物科技股份有限公司 2025 年度持续督导的培训报告 深圳证券交易所： 根据《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等相 关法律法规的要求，中信建投证券股份有限公司（以下简称"中信建投"、"保 荐人"）作为山东三元生物科技股份有限公司（以下简称"三元生物"或"公司"） 首次公开发行股票并上市的保荐人及持续督导机构，三元生物项目组成员于 2025 年 4 月 21 日对三元生物公司到场的董事、监事、高级管理人员、中层以上 管理人员及公司控股股东和实际控制人等相关人员进行了专门培训，并对未到场 的相关人员派发了相关培训资料，督促其认真学习培训内容，本次培训的具体情 况如下： 一、培训时间 2025 年 4 月 21 日 二、培训地点 培训地点及形式：三元生物会议室，线下及线上会议培训 三、培训内容 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》等相关规定，进行上市公司股 东减持股份管理规定、募集资金管理和使用的注意事项、新公司法等监管新规动 态的培训，结合相关法律法规和相关案例进行 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 证券代码：301206 证券简称：三元生物 公告编号：2025-029 山东三元生物科技股份有限公司 关于使用暂时闲置超募资金进行现金管理的进展公告 山东三元生物科技股份有限公司（以下简称"公司"）于 2025 年 1 月 24 日 召开了第五届董事会第五次会议和第五届监事会第五次会议，于 2025 年 2 月 10 日召开了 2025 年第二次临时股东大会，上述会议审议通过了《关于使用暂时闲 置超募资金进行现金管理的议案》。同意公司在不影响日常生产经营和保证超募 资金安全使用的前提下，拟使用不超过 190,000 万元人民币暂时闲置超募资金进 行现金管理。使用期限自公司 2025 年第二次临时股东大会会议审议通过之日起 12 个月内有效，在上述投资额度和使用期限内资金可滚动使用。公司授权管理 层在上述额度范围及期限内行使投资决策、签署相关文件等事宜，具体事项由公 司财务部负责组织实施。具体内容详见公司于 2025 年 1 月 25 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于使用暂时闲置超募 ...

证券代码：301206 证券简称：三元生物 公告编号：2025-030 山东三元生物科技股份有限公司 关于变更签字会计师的公告 1 / 2 从事上市公司审计业务，2024 年开始在容诚会计师事务所执业，2022 年开始为 三元生物提供审计服务；近三年签署过多家上市公司审计报告。 （二）诚信记录 签字注册会计师郝光伟近三年因执业行为受到证监会及其派出机构的监督 管理措施的具体情况详见下表： 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）于 2024 年 8 月 29 日 召开了第五届董事会第二次会议和第五届监事会第二次会议，于 2024 年 9 月 18 日召开了第三次临时股东大会，上述会议审议通过了《关于变更会计师事务所的 议案》。同意改聘容诚会计师事务所（特殊普通合伙）（以下简称"容诚会计师事 务所"）为公司 2024 年度审计机构。具体内容详见公司于 2024 年 8 月 30 日在巨 潮资讯网（www.cninfo.com.cn）披露的《关于拟变更会计师事务所的公告》（公 告编号：2024-068）。 近日 ...

证券代码：301206 证券简称：三元生物 公告编号：2025-028 二、其他说明 山东三元生物科技股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"） 于 2024 年 7 月 8 日 召开了第四届董事会第二十三次会议，会议审议通过了《关于回购公司股份方案 的议案》，同意公司使用自有资金以集中竞价交易方式回购公司已发行的部分人 民币普通股（A 股），用于后期实施股权激励或员工持股计划。本次回购资金总 额不低于人民币 5,000 万元（含），且不超过人民币 10,000 万元（含），回购价格 不超过 35 元/股（含），回购股份的实施期限自公司董事会审议通过回购股份方 案之日起不超过 12 个月，具体回购股份数量以回购结束时实际回购的股份数量 为准。具体内容详见公司于 2024 年 7 月 9 日和 2024 年 7 月 15 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于回购公司股份方案的公告》（公告编号： 2024-045）和《回购报告书》（公告编号： ...

证券代码：301206 证券简称：三元生物 公告编号：2025-027 山东三元生物科技股份有限公司 关于使用暂时闲置超募资金进行现金管理的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）于 2025 年 1 月 24 日 召开了第五届董事会第五次会议和第五届监事会第五次会议，于 2025 年 2 月 10 日召开了 2025 年第二次临时股东大会，上述会议审议通过了《关于使用暂时闲 置超募资金进行现金管理的议案》。同意公司在不影响日常生产经营和保证超募 资金安全使用的前提下，拟使用不超过 190,000 万元人民币暂时闲置超募资金进 行现金管理。使用期限自公司 2025 年第二次临时股东大会会议审议通过之日起 12 个月内有效，在上述投资额度和使用期限内资金可滚动使用。公司授权管理 层在上述额度范围及期限内行使投资决策、签署相关文件等事宜，具体事项由公 司财务部负责组织实施。具体内容详见公司于 2025 年 1 月 25 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于使用暂时闲置超募 ...

证券代码：301206 证券简称：三元生物 公告编号：2025-026 2022 年 11 月，公司对外投资 6,000 万元持有山东沛学生物工程有限公司（以 下简称"沛学生物"）股权，确认为长期股权投资采用权益法进行后续计量。经 查，2023 年末，公司采取收益法对该项长期股权投资进行减值测试时存在以下 问题。 1 / 4 存在问题一：采用的收入增长率、净经营资产增长率、折现率等指标选取依 据不充分。相关取值依据仅为沛学生物所作的盈利预测，未获得进一步证据资料， 未对相关取值进行详细的分析测算。 整改措施： 1、公司深刻反思并进一步优化长期股权投资减值评估方法，已组织财务部 门深入学习《企业会计准则》《资产评估基本准则》及相关法律法规，细化各项 指标选取依据，确保在长期股权投资减值测试过程中数据支持充分、计算方法严 谨、符合行业惯例。 山东三元生物科技股份有限公司 关于山东证监局对公司采取责令改正措施决定的整 改报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）及相关责任人收到中 国证券监督管理委员会山东监管 ...